Table 2 Change from baseline to week 4 in hot flush symptoms and quality of life.
From: Open-label placebos for menopausal hot flushes: a randomized controlled trial
Outcomes, metric | Baseline (observed) | Mean change from baseline to treatment end (week 4) (estimates) | |||||||
|---|---|---|---|---|---|---|---|---|---|
OLP (N = 50) | No-treatment (N = 50) | OLP | No-treatment | Group difference [95% CI] | p | Cohen’s d | |||
M | SD | M | SD | M | M | ||||
Log-transformed hot flush score (diary)a | 2.75 | 0.49 | 2.85 | 0.51 | − 0.52 | − 0.20 | − 0.32 [− 0.43; − 0.21] | < 0.001*** | 0.86 |
Problem rating (HFRS)b | 6.45 | 1.24 | 7.12 | 1.20 | − 1.86 | − 1.43 | − 0.43 [− 1.01; 0.15] | 0.24 | 0.23 |
Hot flush frequency (Diary) | 8.58 | 3.90 | 8.95 | 3.73 | − 2.90 | − 1.77 | − 1.12 [− 1.81; − 0.43] | 0.02* | 0.51 |
QoL overall (MRS-II)c | 18.06 | 9.25 | 18.86 | 7.87 | − 1.75 | 0.78 | − 2.53 [− 4.17; − 0.89] | 0.02* | 0.49 |
QoL Anxiety and Depression (WHQ)d | 75.67 | 21.59 | 75.43 | 16.22 | 2.22 | 0.86 | 1.37 [− 1.82; 4.56] | 0.50 | 0.14 |
QoL Well-being (WHQ) | 80.78 | 16.48 | 80.33 | 14.16 | − 2.01 | − 1.00 | − 1.01 [− 4.73; 2.71] | 0.67 | 0.09 |
QoL Somatic symptoms (WHQ) | 69.47 | 20.39 | 69.60 | 15.60 | 3.18 | − 1.73 | 4.92 [0.05; 9.98] | 0.05 | 0.39 |
QoL Memory/concentration (WHQ) | 55.56 | 29.78 | 50.67 | 24.81 | 4.70 | 1.78 | 2.92 [− 1.63; 7.49] | 0.31 | 0.20 |
QoL Sleep problems (WHQ) | 42.33 | 26.77 | 43.33 | 30.12 | 5.38 | 1.33 | 4.05 [− 2.00; 10.09] | 0.29 | 0.20 |